BioNTech Investor Day Presentation Deck
Long-term in vivo expansion and anti-tumor activity of CAR T cells in
combination with vaccine and BNT151
CAR T-cell expansion and persistence in NSG mice
after repetitive treatment cycles
x fold expansion
(day1 as baseline)
100
10-
0.1-T
0
100
10-
0.1
1°2°3°
Internal data.
CLDN6-LPX
60
Days post ACT
CLDN6-LPX + BNT151
0
4°
20 40
20
5°
40 60
Days post ACT
80 100
80
H
100
x-fold expansion
(day1 as baseline)
100
10-
0.1-
100-
40 60
Days post ACT
Ctrl-LPX+ ctrl-LNP
10-
0.1
Treatment
0
BNT151
0
20
20
80 100
40 60
Days post ACT
80
100
●
700-
600-
500-
400-
300-
200-
100-
Anti-tumor activity of Prodigy-generated human CAR T cells
in OV90 tumor-bearing NSG mice
0
Tumor volume
5 10 15 20 25
Days post ACT
-0
--0--
CLDN6 CAR-T
NUM
NTD
RiboCytokines
+ CLDN6-LPX
+BNT151
+ CLDN6-LPX + BNT151
+ ctrl-LPX + ctrl-LNP
+ CLDN6-LPX
+BNT151
CAR-specific stimulation with CLDN6-LPX leads to persistence
>90 days
BNT151 stimulates repetitively (CAR) T cells. Combination of
CLDN6-LPX and BNT151 superior in stimulating initial expansion
and persistence
CLDN6-LPX, BNT151 expand subtherapeutic CAR T cells in
xenograft models and result in therapeutic activity
BIONTECH
150View entire presentation